Related by context. All words. (Click for frequent words.) 69 chemopreventive agent 66 chemopreventive 64 chemopreventive agents 64 cancer chemoprevention 63 antitumor effect 62 insulin sensitizing 60 oral antiplatelet 60 olaparib 60 dietary modification 60 SERMs 60 statins 59 lowering LDL cholesterol 59 antithrombotic 59 enzastaurin 59 PKCi 59 mTOR inhibitors 59 PARP inhibitors 59 cardio protective 59 tumor subtypes 59 biomarker 58 antiangiogenic 58 antimetastatic 58 adjuvant therapy 58 antitumor 58 MEK inhibitors 58 EGFR pathway 58 histone deacetylase inhibitors 58 biomarkers 58 disease modifying 57 CBLC# 57 molecularly targeted 57 direct thrombin inhibitors 57 proteasome inhibitors 57 lymphatic mapping 57 histone deacetylases 57 sorafenib Nexavar 57 Tyrima 57 rBChE 57 selenium supplementation 57 ganetespib 57 LDL lowering 57 prognostic marker 57 lipid lowering 57 colorectal tumors 57 Hsp# inhibition 57 thiazolidinediones 57 ixabepilone 57 statin therapy 57 anti angiogenic drugs 57 druggable targets 57 vascular disrupting agents 57 panobinostat 57 erlotinib Tarceva 57 cardiovascular morbidity 56 DFMO 56 predictive biomarkers 56 tamoxifen 56 anticancer 56 uric acid lowering 56 dietary antioxidants 56 pharmacogenetic 56 celecoxib 56 hedgehog pathway 56 statin 56 antiangiogenic agents 56 pharmacologic intervention 56 noninvasive imaging 56 lung cancer chemoprevention 56 MMP inhibitors 56 hoFH patients 56 Combination therapy 56 PET imaging 56 HDAC inhibitors 56 COX 2 56 pharmacologic 56 chemosensitivity 56 anticancer activity 56 angiogenesis inhibitors 56 postmenopausal estrogen 56 PSN# [002] 56 prognostic indicator 56 aromatase inhibitor 56 IGF IR 56 cardioprotective effects 56 inhibit angiogenesis 56 soy isoflavones 56 Chemoprevention 56 PXD# 56 statin medications 56 antiangiogenesis 56 neuroprotection 56 selective inhibition 55 insulin sensitizers 55 pomalidomide 55 aromatase inhibitors 55 adjuvant chemotherapy 55 LDL cholesterol lowering 55 pertuzumab 55 anti leukemic 55 PI3K inhibitors 55 hydroxychloroquine 55 adjuvant therapies 55 eniluracil 55 antitumour 55 TCF#L# 55 mTOR inhibition 55 imatinib Gleevec 55 Symadex 55 glucagon receptor 55 antiplatelet therapy 55 immune modulating 55 vorinostat 55 eprotirome 55 temsirolimus 55 mTOR kinase 55 mechanistic insights 55 taxanes 55 HDAC inhibition 55 microtubule targeting 55 prognostic markers 55 curcumin 55 FDG PET 55 inhibit metastasis 55 nonpharmacologic 55 hepatic fibrosis 55 EGFR tyrosine kinase inhibitors 55 antioxidant supplementation 55 diagnostic biomarkers 55 antiplatelet therapies 55 alkylating agent 55 anticancer therapies 55 Abiraterone 55 antidiabetic 55 chemoprevention trials 54 anti VEGF 54 dasatinib 54 RNAi therapeutic targeting PCSK9 54 oral anticancer 54 gefitinib Iressa 54 riociguat 54 anti fibrotic 54 risk stratification 54 vitamin D supplementation 54 obatoclax 54 MiCK assay 54 serum biomarkers 54 pharmacogenetics 54 alpha blocker 54 resolvins 54 ZD# [001] 54 antihypertensive therapy 54 lipid lowering therapy 54 teriparatide 54 anticancer therapy 54 anti amnesic 54 NSAIDs 54 bevacizumab Avastin 54 talabostat 54 xenograft models 54 Akt activation 54 antithrombotic therapy 54 immunomodulatory 54 chemoprotective 54 anti angiogenic agents 54 IGF 1R 54 anti angiogenic 54 Pertuzumab 54 fulvestrant 54 blood clot dissolving 54 testosterone supplementation 54 abiraterone 54 retinoid 54 anti angiogenic therapies 54 GMX# 54 predictive biomarker 54 preclinically 54 androgen receptor 54 antidiabetic agents 54 neuroprotective 54 PGDH 54 novel anticancer 54 Intravenous CP 54 receptor tyrosine kinase inhibitor 54 BRAF inhibitors 54 LY# [003] 54 oral anticoagulants 54 cholesterol lowering 54 antidiabetic drugs 54 aromatase 54 H. pylori eradication 54 cholinesterase inhibitors 54 antiangiogenic agent 54 CDDO Im 54 polyp recurrence 54 neoadjuvant treatment 54 glucose lowering 54 Seewaldt 54 Schisandrin B 54 adjuvant radiation 54 optimal dosing 54 relapsed ovarian cancer 54 dietary supplementation 54 nab paclitaxel 54 tanespimycin 54 cediranib 54 anti TNF 54 anticancer agents 54 selective modulator 54 CA4P 54 pharmacological 54 urate lowering 54 HER2 positive metastatic breast 54 progestins 54 Cristofanilli 54 intensive lipid lowering 54 flavopiridol 54 CR# vcMMAE 54 KRAS mutation 54 #F FDG PET 54 siRNA therapeutics 54 forodesine 53 erythropoietic 53 stratifying patients 53 antiviral therapy 53 prognostic biomarker 53 enzyme inhibitors 53 recurrent prostate cancer 53 GFT# 53 liver fibrosis 53 alvespimycin 53 neoadjuvant chemotherapy 53 acid suppressing 53 prostate cancer CaP 53 forskolin 53 vascular disrupting agent 53 cardiac glycosides 53 colorectal cancer 53 #ME# 53 colorectal polyps 53 mutated BRAF gene 53 EGFR inhibitors 53 Carfilzomib 53 pharmacological approaches 53 antiproliferative effects 53 lung metastasis 53 TZDs 53 atrasentan 53 photodynamic therapy 53 Photodynamic therapy PDT 53 GAP #B# 53 PITX2 methylation 53 radioprotective 53 kinase inhibition 53 tyrosine kinase inhibitors 53 acadesine 53 CCX# 53 immune modulation 53 elevated CRP 53 pterostilbene 53 SIRT1 activation 53 HER2 overexpression 53 pyrimidines 53 rNAPc2 53 TMEM#B 53 N acetylcysteine 53 HER2 positive cancers 53 BZL# 53 neoadjuvant 53 gamma secretase inhibitors 53 molecular biomarkers 53 endothelin receptor antagonists 53 neuro protective 53 pharmacologic stress 53 cetuximab Erbitux 53 pharmacokinetic interactions 53 protein kinase inhibitors 53 neratinib 53 tecarfarin 53 EGF receptor 53 Ceflatonin 53 therapeutic interventions 53 chemotherapeutic 53 investigational therapies 53 Perifosine 53 delta isoform 53 spontaneous regression 53 heavily pretreated 53 sulforaphane 53 mapatumumab 53 Intervention Effectiveness 53 therapeutic armamentarium 53 Micro RNAs 53 IMC A# 53 trastuzumab Herceptin 53 combinability 53 calcium supplementation 53 investigational humanized monoclonal antibody 53 antitumor activity 53 kinase inhibitors 53 inhibit tumor 53 naringenin 53 hormonal therapy 53 figitumumab 53 beta carotene supplementation 53 neuroprotective agent 53 Zolinza 53 COX enzymes 53 endothelin antagonists 53 cMET 53 Pharmacological 53 diagnostic biomarker 53 colon polyps 53 Smac mimetics 53 pharmacotherapeutic 53 mitochondrial toxicity 53 lapatinib Tykerb 53 HNSCC 53 anti anginal 53 treating menopausal symptoms 53 gene amplification 53 OMP #M# 53 angiogenesis inhibition 53 biomarker identification 53 multitargeted 53 Zybrestat 53 esophageal adenocarcinoma 53 dietary interventions 52 EGCG 52 antiestrogen 52 Cloretazine R 52 Celecoxib 52 BRAF inhibitor 52 imetelstat 52 selective inhibitors 52 non pharmacological interventions 52 sapacitabine 52 antiresorptive 52 Cyclin E 52 mycophenolate mofetil 52 antithrombotic agents 52 selective estrogen receptor modulators 52 antiinflammatory 52 CINQUIL 52 bisphosphonates 52 thromboembolic disease 52 small molecule inhibitors 52 chemotherapeutic agent 52 lipid lowering therapies 52 MGd 52 HIF PH inhibitors 52 antitumoral 52 druggable target 52 HGPIN 52 antiarrhythmic 52 adecatumumab 52 bone metastasis 52 act synergistically 52 colorectal adenomas 52 Cisplatin 52 histone methyltransferases HMTs 52 tubulin inhibitor 52 potentiator 52 COX2 52 inhibiting COX 52 SCH # 52 HGS ETR1 52 Bortezomib 52 PIK3CA 52 colorectal liver metastases 52 OXi# 52 bevacizumab Avastin ® 52 molecularly targeted therapy 52 potent anticancer 52 fibrinolytic 52 NEUGENE 52 epigallocatechin gallate EGCG 52 monoclonal antibody therapies 52 Virulizin ® 52 differentiated thyroid 52 calcitriol 52 pro apoptotic 52 immunoregulatory 52 Enzastaurin 52 stratify patients 52 plasma lipid 52 anti angiogenic therapy 52 cardiac toxicity 52 YONDELIS 52 TNFa 52 JAK2 inhibitor 52 beta carotene supplements 52 synthetic lethality 52 Erlotinib 52 radiolabeled 52 angiotensin receptor blockers 52 biologic plausibility 52 PLX# 52 anticancer agent 52 thromboxane A2 52 darapladib 52 EGFR TKIs 52 Hsp# inhibitors 52 gefitinib 52 SERCA2a 52 bortezomib 52 biologic therapy 52 vidofludimus 52 Imatinib 52 CTAP# Capsules 52 chemoradiotherapy 52 fosbretabulin 52 colon tumors 52 dose aspirin 52 metastatic colorectal 52 LHRH antagonists 52 epigenetic therapies 52 protamine 52 prognostic indicators 52 lowering blood glucose 52 viral kinetics 52 Bcl xL 52 gemcitabine Gemzar 52 Blinatumomab 52 heparanase 52 tumor hypoxia 52 oral JAK1 52 tocotrienols 52 angiogenesis inhibitor 52 K ras mutation 52 Hydroxyurea 52 anti atherogenic 52 renin inhibitors 52 prostate tumor 52 HGS# 52 posaconazole 52 Barrett Esophagus 52 pharmacogenetic testing 52 thalidomide Thalomid 52 Clinical Antipsychotic Trials 52 Matthew Meyerson 52 proteasome inhibitor 52 PPARγ 52 sarcosine 52 dasatinib Sprycel 52 ZOLINZA 52 incretin 52 Bisphosphonate 52 trastuzumab Herceptin ® 52 BAY #-# 52 retinoids 52 TRPV1 agonist 52 prognostically 52 renoprotective 52 curative therapy 52 HRPC 52 potent inhibitors 52 Hedgehog pathway 52 Surgical resection 52 infliximab Remicade 52 PARP inhibition 52 tumor histology 52 AdreView 52 regorafenib 52 pro angiogenic 52 medically inoperable 52 Azedra 52 torezolid phosphate 52 CYT# potent vascular disrupting 52 Polyphenon E 52 PARP inhibitor 52 trastuzumab DM1 52 cardiotoxicity 52 Celebrex celecoxib 52 disease progression 52 Panzem 52 mimetics 52 radiation therapy SBRT 52 protease inhibitors 52 Sphingomab 52 phosphate binding 52 neuroprotectant 52 anthracyclines 52 antiplatelet 52 B7 H3 52 Sulforaphane 52 liver metastasis 52 seliciclib 52 Stat5 52 HCV replication 52 paclitaxel Taxol 52 topical calcineurin inhibitors 52 strontium ranelate 52 delafloxacin 52 paricalcitol 52 carcinogenesis 52 c MYC 52 mTOR mammalian target 52 pre malignant lesions 52 antidepressive 52 triglyceride lowering 52 KRN# 52 therapeutic peptide 52 imaging modality 52 endometrial hyperplasia 52 breast irradiation 52 cruciferous vegetables 52 antihypertensive drugs 52 hormonal therapies 52 anastrozole 52 PI3 kinase inhibitors 52 masitinib 52 rapamycin 52 recurrent ovarian cancer 52 sunitinib 51 androgen ablation 51 HERmark 51 antioxidant nutrients 51 metabonomics 51 somatostatin analogs 51 BRAF mutation 51 MAGE A3 ASCI 51 EP #R 51 lipoprotein metabolism 51 metaglidasen 51 Immunotherapeutic 51 tibolone 51 T DM1 51 Xinlay 51 triterpenoids 51 Neugut 51 farletuzumab 51 atacicept 51 presymptomatic 51 EGFR mutation 51 estrogen metabolism 51 Angiotensin receptor blockers 51 HMG CoA reductase inhibitors 51 MGCD# [001] 51 indibulin 51 thienopyridines 51 histone deacetylase HDAC inhibitors 51 HDAC 51 Anthracycline 51 TGFBR1 * 6A 51 postmenopausal hormone 51 molecularly targeted therapies 51 grade gliomas 51 serum PSA 51 Lp PLA2 51 EGFR TKI 51 folate intake 51 adenoma recurrence 51 AP# [003] 51 gamma tocopherol 51 tipifarnib 51 CETP inhibitors 51 Cloretazine ® 51 vandetanib 51 demethylating agents 51 histone deacetylase inhibitor 51 chemotherapeutic drug 51 Panzem NCD 51 immuno suppressive 51 CYC# 51 pioglitazone 51 NPRL2 51 pharmacodynamic markers 51 Aliskiren 51 Lodamin 51 Pazopanib 51 sentinel lymph node biopsy 51 antiplatelet drugs 51 small molecule activators 51 p#INK#a 51 coxibs 51 atherosclerosis regression 51 thetreatment 51 LHRH agonist 51 trastuzumab 51 isoflavone supplements 51 echinocandins 51 Inhaled nitric oxide 51 Muraglitazar 51 amyloid deposition 51 radioimmunotherapy 51 deacetylase inhibitors 51 P#X# 51 PPAR γ 51 Elesclomol 51 molecular imaging 51 statins cholesterol lowering 51 polyphenol 51 glitazones 51 Gefitinib 51 CVD cardiovascular disease 51 axitinib 51 tea polyphenols 51 tumorigenesis 51 endometrial cancers 51 AstraZeneca Arimidex 51 prolongs survival 51 XZK 51 Belldegrun 51 gastrointestinal cancers 51 immunomodulating 51 HER2 positive breast cancer 51 phytoestrogen 51 Adjuvant chemotherapy 51 aromatase inhibitors AIs 51 Epidermal Growth Factor Receptor 51 Molecular imaging 51 ovarian pancreatic 51 DPP4 inhibitors 51 menopausal hormone therapy 51 anti angiogenesis 51 platelet activation 51 mecamylamine 51 p# inhibitors 51 dexamethasone Decadron 51 platelet inhibition 51 XmAb# 51 selective inhibitor 51 perampanel 51 TNFα 51 anti secretory 51 angiotensin receptor blocker ARB 51 Lisofylline LSF 51 epithelial tumors 51 psychopharmacologic 51 HCV protease inhibitors 51 immuno modulatory 51 ExTRACT TIMI 51 immunotherapy 51 Squalamine 51 #beta HSD1 51 metformin 51 deforolimus 51 lipid lowering drugs 51 antidepressant therapy 51 microsphere therapy 51 dyslipidemic 51 immunotoxins 51 integrase inhibitor 51 GnRH agonists 51 Aplidin 51 coenzyme Q# 51 pharmacodynamic properties 51 TACE 51 micrometastases 51 AMN# [001] 51 antitumor efficacy 51 Dr. Pasinetti 51 Hedgehog inhibitor 51 β blockers 51 neoplasia 51 precursor lesions 51 IDO inhibitor 51 enzyme inhibitor 51 endometrial kidney 51 pharmacological therapies 51 MRgFUS 51 sulphonylureas 51 HSP# inhibitor 51 hormonal treatments 51 overlapping toxicities 51 metastatic castration resistant 51 oral prodrug 51 Dasatinib 51 breast endometrial 51 inhibit platelet aggregation 51 Hormonal therapy 51 pan HDAC inhibitor 51 angiotensin receptor blockers ARBs 51 fibrates 51 anticancer drugs 51 mGluR2 NAM 51 modifiable risk 51 endothelin receptor 51 potentially modifiable 51 antigen PSA 51 p# inhibitor 51 ocular disorders 51 idarubicin 51 gastric cancer 51 therapies 51 biodistribution 51 telomerase inhibition 51 bortezomib Velcade 51 antitumor effects 51 mechanistic explanation 51 nephron sparing surgery 51 hematopoietic cancers 51 erlotinib 51 interventional therapies 51 cytoreductive nephrectomy 51 pharmacological interventions 51 prognostic 51 antiplatelet agents 51 prognostic biomarkers 51 PI3K delta 51 NF kappaB 51 immunotoxin 51 colorectal adenoma 51 STRIDE PD 51 lowering cholesterol 51 Pterostilbene 51 antioxidants 51 clomipramine 51 probiotic supplementation 51 flavonoids 51 sulindac 50 immunomodulation 50 multi kinase inhibitor 50 Avastin Tarceva 50 HuLuc# 50 triphendiol 50 EGFR mutation status 50 Cytoxan 50 Doxil ® 50 F FDG PET 50 recurrent glioblastoma multiforme 50 Targretin 50 chromium supplementation 50 oral Xeloda 50 KRAS status 50 estrogen therapy 50 gene expression profiling 50 multivitamin supplements 50 humanised monoclonal antibody 50 allopurinol 50 factor TNF 50 MAPK pathway 50 HER2 expression 50 tomato lycopene 50 Exemestane 50 pharmacological intervention 50 acute leukemias 50 Revlimid lenalidomide 50 raloxifene 50 Bevacizumab 50 NSAID 50 CCL5 50 Panzem R NCD 50 antiangiogenic therapy 50 Deforolimus 50 neuroprotective properties 50 chemotherapeutic agents 50 PITX2 50 warfarin therapy 50 pancreatic cancers 50 NADPH oxidase 50 phase IIb clinical 50 antagomirs 50 inhibiting tumor 50 hypercholesterolemia 50 antiplatelet agent 50 lipoic acid 50 EGFR mutations 50 curative resection 50 cystatin C 50 STAT3 50 thymidylate synthase 50 Antiangiogenic 50 prostate carcinogenesis 50 IAP inhibitors 50 FGFR 50 ellagic acid 50 leukotriene receptor antagonists 50 endocrine therapies 50 selenium intake 50 receptor antagonists 50 CG# [003] 50 Crizotinib 50 postmenopausal hormones 50 PEG SN# 50 cytoprotective 50 molecular abnormalities 50 atherosclerotic disease 50 tumor vascular disrupting 50 Darapladib 50 radionuclide therapy 50 Pralatrexate 50 metastatic kidney 50 Kinase inhibitors 50 kinase inhibitor 50 subclinical atherosclerosis 50 nucleoside analogues 50 photoaging 50 DXL# 50 predictive toxicology 50 atypical antipsychotic medications 50 aldosterone antagonists 50 GPCR targets 50 oral antidiabetic 50 antiproliferative 50 AZILECT ® 50 therapeutic monoclonal antibody 50 Bezielle 50 ovarian carcinoma 50 nutritional supplementation 50 polyphenols 50 androgen deficiency 50 mechanistic insight 50 antifungal therapy 50 ENMD # 50 AEG# 50 Okunieff 50 cilengitide 50 oral rivaroxaban 50 Trofex 50 Talabostat 50 kidney urologic 50 detecting colorectal cancer 50 ALK inhibitors 50 immunohistochemical 50 TRV# [001] 50 herceptin 50 eIF 4E 50 Atiprimod 50 VEGF receptor 50 pharmacologic approaches 50 indolent lymphomas 50 dyslipidemia 50 locoregional recurrence 50 pyridostigmine 50 STK# [002] 50 nonpharmacological 50 pramlintide metreleptin combination 50 targeted radiotherapeutic 50 Degarelix 50 CRAC channel 50 Calcitonin 50 antituberculosis 50 AChE inhibitors 50 sorafenib tablets 50 thiazide diuretics 50 VEGF inhibitors 50 transcriptomics 50 muraglitazar 50 Zevalin consolidation 50 thoracoscopic lobectomy 50 AKT inhibitor 50 molecular weight heparins 50 Cardiotoxicity 50 thyroid nodules 50 precancer 50 Syk 50 Mechanistic studies 50 KRAS variant 50 HIV protease inhibitors 50 refractory acute myeloid 50 antiangiogenic activity 50 Dapagliflozin 50 dosing regimens 50 androgen suppression 50 antianginal 50 conjugated estrogen 50 prostate cancer PCa 50 Velcade bortezomib 50 Sirtuin 50 adjuvant radiotherapy 50 tamoxifen therapy 50 relapsed ALL 50 Cloretazine 50 hormone refractory 50 Idebenone 50 fibrotic disease 50 metastatic RCC 50 MEK ERK 50 RGB # 50 EUS FNA 50 galiximab 50 beta adrenergic 50 biphosphonates 50 glucocorticoids 50 Vidaza azacitidine 50 selective estrogen receptor 50 itraconazole 50 folate supplementation 50 cytotoxics 50 pazopanib 50 randomized trials 50 TLR8 agonist 50 isradipine 50 varespladib 50 dexpramipexole 50 neoadjuvant therapy 50 prostate cancer CRPC 50 PROCHYMAL 50 cannabinoids 50 rhIGFBP 3 50 receptor inhibitor 50 leukotriene receptor antagonist 50 LY# [002] 50 liposomal doxorubicin 50 gastrin 50 sunitinib malate 50 cytostatic 50 oxidative stress inducer 50 anti proliferative 50 pharmacologic treatments 50 sodium glucose cotransporter 50 reversible inhibitor 50 Smac mimetic 50 LRP5 50 cardioprotective 50 cyclooxygenase 2 50 SPARCL 50 anti androgen 50 PSA velocity 50 fondaparinux 50 heparins 50 Mipomersen 50 HIV HCV coinfected 50 endometrial cancer 50 ColoMarker 50 Xanafide 50 limonoids 50 osteopontin 50 antimitotic 50 SIRT1 activator 50 PSA screening 50 spironolactone 50 Bladder Cancer 50 homocysteine lowering 50 empiric therapy 50 ELCAP 50 apoptosis inducing 50 uterine fibroid embolization 50 azoles 50 inhibitors 50 Aurora kinase 50 modulators SERMs 50 PROSTVAC TM 50 ALLHAT 50 BRCA deficient 50 K ras 50 Modrenal 50 statin drugs 50 Cell Lung Cancer 50 experimental therapeutics 50 TriRima 50 anti sickling 50 malignant transformation 50 tesetaxel 50 noscapine 50 etiologic 50 glucocorticoid receptor 50 dose atorvastatin 50 PCK# 50 bevacizumab 50 immunosuppressant drug 50 therapeutic modality 50 Vandetanib 50 Adjuvant therapy 50 PSMA ADC 50 telomerase activation 50 retaspimycin 50 immunomodulatory properties 50 pleiotropic 50 poly ADP ribose polymerase 50 IFRD1 50 oncomodulin 50 GP IIb IIIa inhibitors 50 cardiotoxic 50 molecular mechanisms underlying 50 pancreatic adenocarcinoma 50 pCR 50 HER3 50 Teverelix 50 androgen depletion therapy 50 superficial bladder cancer 50 postmenopausal hormone therapy 50 Amplimexon 50 neurotrophic 50 clinically meaningful 50 molecular profiling 50 Dr. Von Hoff 50 metastatic renal cell carcinoma 50 IGFBP 3 50 transdermal estrogen 50 antioxidant vitamin supplements 50 NF kB pathway 50 cholesterol lowering medication 50 dutasteride 50 adipogenic 50 urothelial cancer 50 oncologic outcomes 50 Estrogens 50 inhibiting telomerase 50 odanacatib 50 Dr. Aman Buzdar 50 pharmacoeconomic 50 antiviral therapies 50 TNF alpha inhibitors 50 adalimumab Humira 50 vinca alkaloid 49 prognostic significance 49 immune modulatory